| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/17/2004 | EP1397146A2 Compositions and methods for inhibiting bone resorption |
| 03/17/2004 | EP1397145A2 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders |
| 03/17/2004 | EP1397142A2 Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| 03/17/2004 | EP1397140A2 Combination of an adenosine a2a-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways |
| 03/17/2004 | EP1397139A1 Pharmaceutical combinations |
| 03/17/2004 | EP1397138A2 Active ingredient combination for treating a dependence on addictive substances or narcotics using medicaments |
| 03/17/2004 | EP1397137A1 Hydantion derivatives as inhibitors of matrix metalloproteinases |
| 03/17/2004 | EP1397135A2 Combination of a pde4 inhibitor and tiotropium or derivative thereof for treating obstructive airways |
| 03/17/2004 | EP1397134A2 Combination of a dopamine d2-receptor agonist and tiotropium or a derivative therof for treating obstructive airways |
| 03/17/2004 | EP1292316A4 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use |
| 03/17/2004 | EP1242119B1 Combinations for the treatment of dna viral infections comprising a loop diuretic and a cardiac glycoside |
| 03/17/2004 | EP1214397B1 Method for the selective protection of proliferating normal cells and the selective eradication of tumor cells having an inactive p53 pathway |
| 03/17/2004 | EP1176871A4 Novel beta-secretase and modulation of beta-secretase activity |
| 03/17/2004 | EP1039890B1 Novel salts of metformin and method |
| 03/17/2004 | EP0986373B1 Drug targeting system, method of its preparation and its use |
| 03/17/2004 | EP0975775B1 Regulatory system for inducible expression of genes with lambdoid promoters |
| 03/17/2004 | EP0915974B1 Modified tie-2-receptor ligands |
| 03/17/2004 | EP0762881B1 Use of active agents for the manufacture of medicaments for the treatment of rheumatoid arthritis |
| 03/17/2004 | CN1483043A Chitosan-containing multicomponent composition and process for preparing the same |
| 03/17/2004 | CN1483039A Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 03/17/2004 | CN1483035A Sulfamidothienopyrimidines |
| 03/17/2004 | CN1483026A Benzoylpyridazine |
| 03/17/2004 | CN1483021A Novel 1, 2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism |
| 03/17/2004 | CN1482920A Compositions for the treatment of coccidiosis |
| 03/17/2004 | CN1482918A Modulation of smr1-nep interactions in cns disorders giving rise to mental disorders |
| 03/17/2004 | CN1482917A New therapeutic uses of smr1 peptides |
| 03/17/2004 | CN1482912A Heteroaryl urea neuropeptide yy5 receptor antagonists |
| 03/17/2004 | CN1482864A Composition and method |
| 03/17/2004 | CN1141975C Process for preparing xenogenous or autogenous tumor vaccine of liposome |
| 03/17/2004 | CN1141937C Pharmaceutical composition containing tramadol for preparing medicine of curing hemicrania and the like |
| 03/16/2004 | US6706947 Method for screening for agents against cancer using an immunosuppression animal model |
| 03/16/2004 | US6706762 Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases |
| 03/16/2004 | US6706759 Method of treating cancer using dithiocarbamate derivatives |
| 03/16/2004 | US6706743 β3 adrenergic receptor agonists and uses thereof |
| 03/16/2004 | US6706724 Antitumor agents; antiinflammatory agents; analgesics; antipyretic agent |
| 03/16/2004 | US6706720 Heterocyclic dihydropyrimidine compounds |
| 03/16/2004 | US6706717 Thiazolyl inhibitors of Tec family tyrosine kinases |
| 03/16/2004 | US6706713 Conjugate for treating inflammatory infectious and/or skin diseases |
| 03/16/2004 | US6706711 Substituted diaminopyrazoles; treating diseases, such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. coatings for implantable medical devices, such as prostheses, artificial valves, etc. |
| 03/16/2004 | US6706691 Bioavailability of compositions metabolized by the gut p450 isozymes |
| 03/16/2004 | US6706689 Administering glucagon like peptide-1 (glp-1), where the patient is not suffering from a q-wave myocardial infarction |
| 03/16/2004 | US6706687 Platelet-derived growth factor D |
| 03/16/2004 | US6706686 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| 03/16/2004 | US6706514 Polypeptides capable of interacting with the human topoisomerase IIIα |
| 03/16/2004 | US6706508 Isolated polypeptide comprising specified amino acid sequence, which exhibits ornithine carbamoyltransferase activity |
| 03/16/2004 | US6706491 Reagents and methods for identifying and modulating expression of genes regulated by p21 |
| 03/16/2004 | US6706290 Calcium chelation demineralization then disinfecting; preventing kidney, salivary gland and dental pulp stones and atherosclerosis |
| 03/16/2004 | US6706274 Differential delivery of nitric oxide |
| 03/16/2004 | US6706266 Oncostatin M antagonists |
| 03/16/2004 | US6706263 Composition for alleviating symptoms of uremia in patients |
| 03/16/2004 | CA2331446C Biodegradable sustained-release alginate gels |
| 03/16/2004 | CA2294399C Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the treatment of cancer |
| 03/11/2004 | WO2004021010A2 Method of diagnosing colon and gastric cancers |
| 03/11/2004 | WO2004020631A2 Genetic suppression and replacement |
| 03/11/2004 | WO2004020468A2 Interferon beta-like molecules for treatment of cancer |
| 03/11/2004 | WO2004020435A1 Piperidinyl compounds that selectively bind integrins |
| 03/11/2004 | WO2004020403A2 A composition and method to augment and sustain neurotransmitter production |
| 03/11/2004 | WO2004020014A2 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 03/11/2004 | WO2004019986A1 Methods of treating acute respiratory distress syndrome |
| 03/11/2004 | WO2004019985A1 Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| 03/11/2004 | WO2004019984A1 Novel combination of glucocorticoids and pde-4-inhibitors for treating respiratory diseases, allergic diseases, asthma and copd |
| 03/11/2004 | WO2004019982A1 Remedy |
| 03/11/2004 | WO2004019981A1 Method of diffrentiation and maturation of non-nerve cells into nerve cells, agent therefor and method of searching for the agent |
| 03/11/2004 | WO2004019955A1 The use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis |
| 03/11/2004 | WO2004019954A1 Estrogen replacement regimen |
| 03/11/2004 | WO2004019951A1 REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS |
| 03/11/2004 | WO2004019949A1 Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders |
| 03/11/2004 | WO2004019937A1 Pharmaceutical composition of metaxalone with enhanced oral bioavailability |
| 03/11/2004 | WO2004019931A1 Method to treat laminitis and reduce dietary intake for horses |
| 03/11/2004 | WO2004019929A1 Composition based on triethyl citrate for the treatment of bacterial infections of the skin |
| 03/11/2004 | WO2004019917A1 Device for release of a drug containing oseltamivir and a h1 antagonist |
| 03/11/2004 | WO2004019907A1 Methods and reagents for treating infections of clostridium difficile and diseases associated therewith |
| 03/11/2004 | WO2004019885A2 Fast dissolving film delivery of nucleotides that inhibit the unpleasant taste of bitter tasting medications |
| 03/11/2004 | WO2004019876A2 Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure |
| 03/11/2004 | WO2004004705A3 Pharmaceutical formulations for preparing drink products |
| 03/11/2004 | WO2004004699A3 Use of dantrolene, a ryanodine antagonist, in treating neural injury |
| 03/11/2004 | WO2004002462A3 Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder |
| 03/11/2004 | WO2004000219A3 Stabilized formulations of alpha adrenergic receptor antagonists and uses thereof |
| 03/11/2004 | WO2003099200A3 Composition and method for the treatment of diaper rash using natural products |
| 03/11/2004 | WO2003097698A8 Treatment of cancer by the use of anti fas antibody |
| 03/11/2004 | WO2003096977A3 Methods of treating hepatitis |
| 03/11/2004 | WO2003095662A3 Simultaneous detection of two analytes produced by a cell under the influence of a putative agent using a pin coated assay system |
| 03/11/2004 | WO2003094840A3 Induction of antigen specific immunologic tolerance |
| 03/11/2004 | WO2003089615A3 Antiviral inhibitions of capsid proteins |
| 03/11/2004 | WO2003088915A3 Novel sodium channel blockers |
| 03/11/2004 | WO2003086308A3 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 03/11/2004 | WO2003084342A3 Method and dietary composition for improving lipid digestibility |
| 03/11/2004 | WO2003075899A3 Combinations comprising epothilone derivatives and alkylating agents |
| 03/11/2004 | WO2003072737A3 Biological inhibitions induced by contact inhibitory factor |
| 03/11/2004 | WO2003071268A3 Method for discovering pharmacologically active substances |
| 03/11/2004 | WO2003068164A3 Dosing regimen for gemcitabine hcv therapy |
| 03/11/2004 | WO2003068162A3 Modified fluorinated nucleoside analogues |
| 03/11/2004 | WO2003059395A3 Antisense compounds directed against human csf-1 |
| 03/11/2004 | WO2003059323A3 Stable salts of o-acetylsalicylic acid containing basic amino acids ii |
| 03/11/2004 | WO2003057201A3 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 03/11/2004 | WO2003054141A3 Sperm-specific cation channel, catsper2, and uses therefor |
| 03/11/2004 | WO2003046007A3 Treatment of micro-organism infection |
| 03/11/2004 | WO2003030813A3 Anti-irritating rosacea treatment |
| 03/11/2004 | WO2003026479A3 Methods of suppressing microglial activation |
| 03/11/2004 | WO2003015690B1 Method for treating primary insomnia |